Datasets:

Haxirus

/

Fine-Tuning_Dataset

like 0

Does Abciximab and Secukinumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Secukinumab, and the severity of the interaction is minor.

Does Abciximab and Selegiline interact?

It has been reported that concomitant administration of antiplatelet agents and monoamine oxidase inhibitor antidepressants that increase the levels of serotonin are associated with an increase in hemorrhage. This interaction is due to the inhibition of serotonin reuptake in platelets which produces a reduction of serotonin to even 1% of the normal quantity. Serotonin is very important for the aggregation of platelets and the lack of serotonin does not allow the normal aggregation process of the platelets. In short, The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Sertraline interact?

The concomitant use of sertraline and anticoagulants can increase the risk of bleeding due to additive effects. Clinical studies and case reports have shown an association between serotonin reuptake inhibitors (such as sertraline) and increased incidence of gastrointestinal bleeding. Effects that also may occur include, epistaxis, ecchymosis, hematoma, and petechiae. In some cases severe and fatal hemorrhage can occur. Platelets normally release serotonin after a vascular injury, leading to vasoconstriction and alterations in platelet shape that ultimately lead to platelet aggregation. SSRI drugs such as sertraline are inhibitors of the serotonin transporter, which normally facilitates the uptake of serotonin into platelets, which cannot synthesize serotonin themselves. Reducing the amount of serotonin that is taken up into the cell inhibits the formation of clots, thereby increasing the risk of bleeding. In short, The risk or severity of bleeding can be increased when Sertraline is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Sildenafil interact?

Sildenafil treatment can cause epistaxis (i.e. nosebleeds) as a side effect1 - the incidence of epistaxis is higher in patients receiving concomitant therapy with an oral vitamin K antagonist. In short, The risk or severity of hemorrhage can be increased when Abciximab is combined with Sildenafil, and the severity of the interaction is minor.

Does Abciximab and Siltuximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Siltuximab, and the severity of the interaction is minor.

Does Abciximab and Sirolimus interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Sirolimus, and the severity of the interaction is minor.

Does Abciximab and Sodium citrate interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Sodium citrate, and the severity of the interaction is moderate.

Does Abciximab and Sorafenib interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Sorafenib, and the severity of the interaction is minor.

Does Abciximab and Sotrovimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Sotrovimab, and the severity of the interaction is minor.

Does Abciximab and Soybean oil interact?

Soybean oil is a food source of high vitamin K1.1 Vitamin K1 serves as a vitamin required for blood coagulation,3 and may counteract the anticoagulant activity of vitamin K antagonists such as warfarin. While there were no drug-interaction studies that examined the effect of soybean on the therapeutic efficacy of anticoagulant drugs, one case report documents a patient who was stable on warfarin therapy developing subtherapeutic INR values after ingesting soy milk. The case study suggests the cause of this effect to be increased consumption of vitamin K. Upon discontinuation of the soy milk, INR values returned to therapeutic concentrations within two weeks. In short, The therapeutic efficacy of Abciximab can be decreased when used in combination with Soybean oil, and the severity of the interaction is minor.

Does Abciximab and Spesolimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Spesolimab, and the severity of the interaction is minor.

Does Abciximab and Streptokinase interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Streptokinase, and the severity of the interaction is moderate.

Does Abciximab and Streptozocin interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Streptozocin, and the severity of the interaction is minor.

Does Abciximab and Sugammadex interact?

Coagulopathy and bleeding events have been observed with sugammadex therapy; co-administration of drugs affecting hemostasis and known to cause bleeding, such as anticoagulants, with sugammadex may lead to increased risk for bleeding and hemorrhage. In short, The risk or severity of bleeding and hemorrhage can be increased when Abciximab is combined with Sugammadex, and the severity of the interaction is minor.

Does Abciximab and Sulfasalazine interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Sulfinpyrazone interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Sulindac interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Sulodexide interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Sulodexide, and the severity of the interaction is moderate.

Does Abciximab and Susoctocog alfa interact?

Blood coagulation factors promote the blood coagulation pathways to ultimately form the insoluble fibrin clot. In contrast, fibrinolytic agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin to break down the insoluble clot [A38173]. Desired procoagulant effects of blood coagulation factors may be reduced with the combination use of fibrinolytic agents. In short, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Abciximab, and the severity of the interaction is major.

Does Abciximab and Sutimlimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Sutimlimab, and the severity of the interaction is minor.

Does Abciximab and Synthetic Conjugated Estrogens, A interact?

Estrogens activate the coagulation pathway via increasing plasma fibrinogen and the activity of coagulation factors such as factors VII and X. Co-administration of estrogens with anticoagulant agents may interfere with the anticoagulant actions of those agents. In short, Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Synthetic Conjugated Estrogens, B interact?

Estrogens activate the coagulation pathway via increasing plasma fibrinogen and the activity of coagulation factors such as factors VII and X. Co-administration of estrogens with anticoagulant agents may interfere with the anticoagulant actions of those agents. In short, Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tacrolimus interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Tacrolimus, and the severity of the interaction is minor.

Does Abciximab and Tafasitamab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tafasitamab, and the severity of the interaction is minor.

Does Abciximab and Tamoxifen interact?

Coadministration of tamoxifen with anticoagulant drugs has been shown to produce an increase in the anticoagulant effect producing cases of bleeding. However, this combination of drugs is concomitantly prescribed as tamoxifen increases the risk of venous thromboembolism. The mechanism of action has not been fully elucidated. In short, The risk or severity of bleeding can be increased when Tamoxifen is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tauroursodeoxycholic acid interact?

Antiplatelet agents may enhance the bleeding risk when administered with cholic acid due to the additive effects of both drugs. In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tauroursodeoxycholic acid, and the severity of the interaction is moderate.

Does Abciximab and Tazobactam interact?

Tazobactam is frequently coadministered in a single agent (piperacillin-tazobactam), which may increase the risk of bleeding. When coadministered with anticoagulants or other drugs that increase the risk of bleeding, hemorrhage may result, especially at higher doses of agents that predispose to bleeding. In short, The risk or severity of bleeding can be increased when Tazobactam is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tedizolid phosphate interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Tedizolid phosphate, and the severity of the interaction is minor.

Does Abciximab and Temozolomide interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Temozolomide, and the severity of the interaction is minor.

Does Abciximab and Temsirolimus interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Temsirolimus, and the severity of the interaction is minor.

Does Abciximab and Tenecteplase interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Tenecteplase, and the severity of the interaction is moderate.

Does Abciximab and Teniposide interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Teniposide, and the severity of the interaction is minor.

Does Abciximab and Tenoxicam interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Teplizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Teplizumab, and the severity of the interaction is minor.

Does Abciximab and Testosterone cypionate interact?

Testosterone and derivatives may increase sensitivity to oral anticoagulants, increasing the risk of bleeding; however, the mechanism has not been fully elucidated. Although product labeling and various studies support that testosterone may potentiate anticoagulant effects, certain studies suggest that testosterone may increase the risk of venous thromboembolism (VTE). Despite the above findings, it is generally accepted that testosterone potentiates the anticoagulant effects of other drugs. In short, Testosterone cypionate may increase the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Testosterone enanthate interact?

Testosterone and derivatives may increase sensitivity to oral anticoagulants, increasing the risk of bleeding; however, the mechanism has not been fully elucidated. Although product labeling and various studies support that testosterone may potentiate anticoagulant effects, certain studies suggest that testosterone may increase the risk of venous thromboembolism (VTE). Despite the above findings, it is generally accepted that testosterone potentiates the anticoagulant effects of other drugs. In short, Testosterone enanthate may increase the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Testosterone propionate interact?

Testosterone and derivatives may increase sensitivity to oral anticoagulants, increasing the risk of bleeding; however, the mechanism has not been fully elucidated. Although product labeling and various studies support that testosterone may potentiate anticoagulant effects, certain studies suggest that testosterone may increase the risk of venous thromboembolism (VTE). Despite the above findings, it is generally accepted that testosterone potentiates the anticoagulant effects of other drugs. In short, Testosterone propionate may increase the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Testosterone undecanoate interact?

Testosterone and derivatives may increase sensitivity to oral anticoagulants, increasing the risk of bleeding; however, the mechanism has not been fully elucidated. Although product labeling and various studies support that testosterone may potentiate anticoagulant effects, certain studies suggest that testosterone may increase the risk of venous thromboembolism (VTE). Despite the above findings, it is generally accepted that testosterone potentiates the anticoagulant effects of other drugs. In short, Testosterone undecanoate may increase the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Testosterone interact?

Testosterone and derivatives may increase sensitivity to oral anticoagulants, increasing the risk of bleeding; however, the mechanism has not been fully elucidated. Although product labeling and various studies support that testosterone may potentiate anticoagulant effects, certain studies suggest that testosterone may increase the risk of venous thromboembolism (VTE). Despite the above findings, it is generally accepted that testosterone potentiates the anticoagulant effects of other drugs. In short, Testosterone may increase the anticoagulant activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tetanus immune globulin, human interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tetanus immune globulin, human, and the severity of the interaction is minor.

Does Abciximab and Tezepelumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tezepelumab, and the severity of the interaction is minor.

Does Abciximab and Thalidomide interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Thalidomide, and the severity of the interaction is minor.

Does Abciximab and Thiotepa interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Thiotepa, and the severity of the interaction is minor.

Does Abciximab and Tiaprofenic acid interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tibolone interact?

Tibolone has the tendency to increase blood fibrinolytic activity, leading to lower fibrinogen levels, higher antithrombin III, plasminogen and fibrinolytic activity values. Co-administration of tibolone with anticoagulant agents may lead to enhanced therapeutic action and anticoagulant effect of those drugs. In short, Tibolone may increase the anticoagulant activities of Abciximab, and the severity of the interaction is minor.

Does Abciximab and Ticagrelor interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Ticagrelor, and the severity of the interaction is moderate.

Does Abciximab and Ticlopidine interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Ticlopidine is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tildrakizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tildrakizumab, and the severity of the interaction is minor.

Does Abciximab and Tinzaparin interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Tinzaparin, and the severity of the interaction is moderate.

Does Abciximab and Tioguanine interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Tioguanine, and the severity of the interaction is minor.

Does Abciximab and Tipranavir interact?

In vitro experiments have demonstrated that tipranavir was observed to inhibit human platelet aggregation at levels consistent with exposures observed in patients receiving ritonavir. In rats, tipranavir treatment alone induced dose-dependent changes in coagulation parameters, bleeding incidents and death. Therefore, the bleeding risk of antiplatelet agents may be increased with the concomitant use of tipranavir. In short, Tipranavir may increase the antiplatelet activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tirofiban interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Tirofiban is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tislelizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tislelizumab, and the severity of the interaction is minor.

Does Abciximab and Tisotumab vedotin interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tisotumab vedotin, and the severity of the interaction is minor.

Does Abciximab and Tocilizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tocilizumab, and the severity of the interaction is minor.

Does Abciximab and Tofacitinib interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Tofacitinib, and the severity of the interaction is minor.

Does Abciximab and Tolfenamic acid interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tolmetin interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Topotecan interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Topotecan, and the severity of the interaction is minor.

Does Abciximab and Toremifene interact?

Toremifene has been reported to produce vaginal bleeding as a common effect. This effect is mainly observed when toremifene is given in high doses. Hence, concomitant administration of toremifene and anticoagulants should be done cautiously as there is a potential increase in the risk and severity of bleeding events. In short, The risk or severity of bleeding can be increased when Toremifene is combined with Abciximab, and the severity of the interaction is minor.

Does Abciximab and Toripalimab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Toripalimab, and the severity of the interaction is minor.

Does Abciximab and Trabectedin interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Trabectedin, and the severity of the interaction is minor.

Does Abciximab and Tralokinumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tralokinumab, and the severity of the interaction is minor.

Does Abciximab and Tranylcypromine interact?

It has been reported that concomitant administration of antiplatelet agents and monoamine oxidase inhibitor antidepressants that increase the levels of serotonin are associated with an increase in hemorrhage. This interaction is due to the inhibition of serotonin reuptake in platelets which produces a reduction of serotonin to even 1% of the normal quantity. Serotonin is very important for the aggregation of platelets and the lack of serotonin does not allow the normal aggregation process of the platelets. In short, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Trastuzumab deruxtecan interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Trastuzumab deruxtecan, and the severity of the interaction is minor.

Does Abciximab and Trastuzumab emtansine interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Trastuzumab emtansine, and the severity of the interaction is minor.

Does Abciximab and Trastuzumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Trastuzumab, and the severity of the interaction is minor.

Does Abciximab and Trazodone interact?

Platelets normally release serotonin, and this process is essential in homeostasis, stabilizing blood flow.3 Combining an antiplatelet agent or anticoagulant with trazodone may increase the risk of bleeding of antiplatelet agents due to its serotonergic effects, which interfere with platelet release of serotonin. In short, The risk or severity of bleeding can be increased when Trazodone is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Tremelimumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Tremelimumab, and the severity of the interaction is minor.

Does Abciximab and Treprostinil interact?

Prostacyclin analogs may interfere with platelet aggregation, further potentiating the bleeding risk of antiplatelet agents. In short, Treprostinil may increase the antiplatelet activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Triamcinolone interact?

Concomitant use of anticoagulants and triamcinolone can inhibit the effect of anticoagulants.1,2,3,4,5 In short, The therapeutic efficacy of Abciximab can be decreased when used in combination with Triamcinolone, and the severity of the interaction is moderate.

Does Abciximab and Triflusal interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Triflusal, and the severity of the interaction is moderate.

Does Abciximab and Trolamine salicylate interact?

.Concurrent use of salicylates and anticoagulants may lead to increased anticoagulant activity and therefore an increased risk of bleeding, due to additive anticoagulant effects. In short, The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Turoctocog alfa pegol interact?

Blood coagulation factors promote the blood coagulation pathways to ultimately form the insoluble fibrin clot. In contrast, fibrinolytic agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin to break down the insoluble clot [A38173]. Desired procoagulant effects of blood coagulation factors may be reduced with the combination use of fibrinolytic agents. In short, The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Abciximab, and the severity of the interaction is major.

Does Abciximab and Turoctocog alfa interact?

Blood coagulation factors promote the blood coagulation pathways to ultimately form the insoluble fibrin clot. In contrast, fibrinolytic agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin to break down the insoluble clot [A38173]. Desired procoagulant effects of blood coagulation factors may be reduced with the combination use of fibrinolytic agents. In short, The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Abciximab, and the severity of the interaction is major.

Does Abciximab and Ublituximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Ublituximab, and the severity of the interaction is minor.

Does Abciximab and Ulipristal interact?

Systemic hormonal contraceptives, such as the subject drug, are known to increase the risk of venous thromboembolism (VTE).4,1,3 While specific data regarding the concomitant use of hormonal contraceptives and anticoagulants is sparse, it follows that the procoagulant effects of hormonal contraceptives may oppose the therapeutic effects of anticoagulants, lowering their efficacy and increasing the risk of clotting. The estrogen component of combined hormonal contraceptives appears to the be the primary culprit in their induction of hypercoagulability - its effects appear to be driven by alterations to procoagulant proteins (i.e. clotting factors) and an induced resistance to activated protein C (APC), an endogenous anticoagulant. While it was previously thought that first-pass metabolism of oral contraceptives through the liver was responsible for their prothrombotic effect, more recent studies have suggested that alternative routes of administration (i.e. routes that bypass first-pass metabolism) do not improve the risk of clotting, and this is reflected in the FDA labeling for these non-oral contraceptive options. Progestin-only contraceptives do not appear to carry the same risk of thrombotic events as do estrogen-containing contraceptives. This interaction is likely to be more significant in patients with other risk factors for hormonal contraceptive-induced thrombotic events, such as smoking, age >35, obesity, and hypertension. In short, The therapeutic efficacy of Abciximab can be decreased when used in combination with Ulipristal, and the severity of the interaction is moderate.

Does Abciximab and Urokinase interact?

Urokinase is a thrombolytic enzyme with a potential risk to cause serious bleeding events. Fatalities due to hemorrhage, including intracranial and retroperitoneal, have been reported in association with urokinase therapy. Concurrent administration of urokinase with other anticoagulants may further increase the risk of serious bleeding due to a synergistic anticoagulant effect. In short, Urokinase may increase the anticoagulant activities of Abciximab, and the severity of the interaction is major.

Does Abciximab and Ursodeoxycholic acid interact?

Antiplatelet agents may enhance the bleeding risk when administered with cholic acid due to the additive effects of both drugs. In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Ursodeoxycholic acid, and the severity of the interaction is moderate.

Does Abciximab and Ustekinumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Ustekinumab, and the severity of the interaction is minor.

Does Abciximab and Valdecoxib interact?

Both anticoagulants and non-steroidal anti-inflammatory agents are associated with a risk for bleeding events. Concomitant use of anticoagulants with over-the-counter NSAIDs may significantly increase the risk for gastrointestinal hemorrhage while concomitant use of anticoagulants with acetaminophen may lead to increased risk for general all-site bleeding events. NSAIDs such as ibuprofen are substrates of CYP2C9, which may also interfere with the metabolism of S-warfarin and further increase the risk for warfarin-associated bleeding. In short, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Vedolizumab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Abciximab is combined with Vedolizumab, and the severity of the interaction is minor.

Does Abciximab and Venlafaxine interact?

Venlafaxine can cause platelet aggregation and prolong blood clot formation time.1 Concomitant use of venlafaxine with an anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of venlafaxine on the release of serotonin by platelets. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Venlafaxine, and the severity of the interaction is minor.

Does Abciximab and Vinblastine interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Vinblastine, and the severity of the interaction is minor.

Does Abciximab and Vindesine interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Vindesine, and the severity of the interaction is minor.

Does Abciximab and Vinorelbine interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Vinorelbine, and the severity of the interaction is minor.

Does Abciximab and Vitamin E interact?

Alpha-tocopherol, a form of Vitamin E, inhibits the activity of protein kinase C, an enzyme involved in cell proliferation and differentiation in platelets, therefore inhibiting the production of platelets. Vitamin E also increases the expression of two enzymes that suppress arachidonic acid metabolism, which in turn increases the release of prostacyclin from the endothelium. The prostacyclin dilates blood vessels and inhibits platelet aggregation, increasing the risk of bleeding. In short, Vitamin E may increase the antiplatelet activities of Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Von Willebrand factor human interact?

Blood coagulation factors promote the blood coagulation pathways to ultimately form the insoluble fibrin clot. In contrast, fibrinolytic agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin to break down the insoluble clot [A38173]. Desired procoagulant effects of blood coagulation factors may be reduced with the combination use of fibrinolytic agents. In short, The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Abciximab, and the severity of the interaction is major.

Does Abciximab and Vorapaxar interact?

Vorapaxar is an anti-platelet agent with an increased risk for bleeding in proportion to the patient’s underlying bleeding risk. Concomitant use of vorapaxar with other medications known to increase the risk of bleeding, such as anticoagulants, may lead to increased risk for non-fatal and fatal bleeding events including intracranial hemorrhage. In short, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Abciximab, and the severity of the interaction is major.

Does Abciximab and Vorinostat interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Vorinostat, and the severity of the interaction is minor.

Does Abciximab and Vortioxetine interact?

Prescribing information for vortioxetine states that its concomitant use with other drugs capable of interfering with hemostasis may lead to an increased risk of hemorrhage. Platelet aggregation - and consequently hemostasis - is mediated in part by serotonin, and for this reason the inhibition of serotonin transporters by drugs like vortioxetine may also interfere with hemostasis. The co-administration of additional agents that may cause the same or similar effects (e.g. antiplatelet agents) may therefore result in additive antiplatelet activity and an increased risk of bleeding episodes. In short, The risk or severity of bleeding can be increased when Vortioxetine is combined with Abciximab, and the severity of the interaction is moderate.

Does Abciximab and Warfarin interact?

Both antiplatelet agents and anticoagulants are associated with a risk of bleeding when administered alone. The concomitant use of these agents may further increase the risk for fatal and non-fatal bleeding events, including gastrointestinal hemorrhage. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Warfarin, and the severity of the interaction is moderate.

Does Abciximab and Zidovudine interact?

As their name suggested, myelosuppressive agents can decrease the production of cells found in the bone marrow, including thrombocytes.5,1 Low levels of thrombocytes, or thrombocytopenia, can increase the risk of bleeding due to the inability to form blood clots. Therefore, concomitant administration of agents that prevent thrombotic events such as antiplatelet agents can further exacerbate this risk into abnormal bleeding. In short, The risk or severity of bleeding can be increased when Abciximab is combined with Zidovudine, and the severity of the interaction is minor.

Does Adalimumab and Abatacept interact?

Since adalimumab and abatacept are both immunosuppressants, co-administration of adalimumab and abatacept can increase the risk of infection. In short, The risk or severity of infection can be increased when Adalimumab is combined with Abatacept, and the severity of the interaction is moderate.

Does Adalimumab and Abciximab interact?

Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Abciximab, and the severity of the interaction is minor.

Does Adalimumab and Abemaciclib interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Abemaciclib can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Abrocitinib interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Abrocitinib can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Acalabrutinib interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Acalabrutinib can be increased when combined with Adalimumab, and the severity of the interaction is major.

Does Adalimumab and Acebutolol interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Acebutolol can be increased when combined with Adalimumab, and the severity of the interaction is moderate.

Does Adalimumab and Acenocoumarol interact?

The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Acenocoumarol can be increased when combined with Adalimumab, and the severity of the interaction is major.